As cardiovascular disease continues to be the leading cause of death in China—accounting for over 40% of all fatalities—atherosclerotic cardiovascular disease (ASCVD) poses an escalating public health challenge. Rising living standards and rapid population aging have intensified the burden of dyslipidemia and its complications, making effective lipid management a cornerstone of ASCVD prevention and control.
Against this backdrop, Hymecalmib (marketed as Saiximei), a domestically developed first-in-class cholesterol absorption inhibitor approved in China in 2021, has emerged as a promising therapeutic option. As a second-generation NPC1L1 inhibitor, Hymecalmib selectively targets the Niemann-Pick C1-like 1 protein on the brush border of enterocytes, thereby reducing intestinal absorption of dietary and biliary cholesterol. Its mechanism is complementary to statins—which inhibit hepatic cholesterol synthesis—enabling synergistic LDL-C lowering when used in combination.
A key factor underpinning Hymecalmib’s favorable safety profile is its distinctive dual-elimination pathway. Unlike many drugs reliant predominantly on hepatic or renal clearance, Hymecalmib undergoes balanced metabolism and excretion via both liver and kidney pathways, with an overall systemic clearance rate of approximately 93%. This efficient dual-channel elimination minimizes the risk of drug accumulation, even with long-term administration—a critical advantage for chronic therapy.
Clinical pharmacokinetic studies further support its robust safety in vulnerable populations. In patients with mild-to-moderate hepatic impairment, exposure to total Hymecalmib—as measured by area under the curve (AUC)—increased only 1.4- to 1.5-fold compared with healthy controls; no dose adjustment was required. Similarly, in patients with severe renal impairment, AUC rose by just ~1.3-fold, again without necessitating dosage modification. These findings position Hymecalmib as a reliable option for individuals traditionally considered high-risk for adverse drug reactions due to organ dysfunction.
Real-world evidence from Chinese clinical trials reinforces these observations. Over ten investigator-initiated and multicenter studies conducted exclusively in Chinese adults demonstrate that adding Hymecalmib to background statin therapy reduces low-density lipoprotein cholesterol (LDL-C) by an additional ~16%—an effect comparable to high-intensity statin monotherapy. Importantly, long-term combination treatment did not elevate the incidence of adverse events beyond that observed with statin monotherapy. Patient-reported tolerability remained high, with no signal of increased myopathy, hepatotoxicity, or gastrointestinal disturbance attributable to Hymecalmib.
Collectively, Hymecalmib’s pharmacokinetic properties, organ-function–informed dosing guidance, and consistent safety outcomes across diverse Chinese patient cohorts affirm its strong benefit–risk profile. It represents a valuable therapeutic alternative—notably for patients with statin intolerance or those failing to achieve LDL-C goals on maximally tolerated statin regimens. While individualized treatment decisions must always be guided by clinician assessment, Hymecalmib offers both efficacy and reassurance for sustained, guideline-directed lipid management.